Omega-3 fatty acids in health and disease: Part 2 - Health effects of omega-3 fatty acids in autoimmune diseases, mental health, and gene expression

Journal of Medicinal Food

Volumn 8, Issue 2, 2005, Pages 133-148

  Shahidi, Fereidoon ^a   Miraliakbari, Homan ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Autoimmune diseases; Gene expression; Mental health; Omega 3 fatty acids

Indexed keywords

ALKALINE PHOSPHATASE; ARACHIDONIC ACID; CORN OIL; CYCLOSPORIN; DOCOSAHEXAENOIC ACID; FISH OIL; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; LINOLENIC ACID; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MYELOPEROXIDASE; OMEGA 3 FATTY ACID; PERILLA OIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; PREDNISOLONE; PROSTAGLANDIN E2; SAFFLOWER OIL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; SUNFLOWER OIL; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ASTHMA; AUTOIMMUNE DISEASE; BRAIN DEVELOPMENT; BRONCHITIS; CLINICAL TRIAL; CROHN DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DEPRESSION; DIET SUPPLEMENTATION; DISEASE COURSE; ENTERITIS; ESSENTIAL FATTY ACID DEFICIENCY; EYE DEVELOPMENT; GENE EXPRESSION; GRAFT REJECTION; HUMAN; ICOSANOID METABOLISM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIPID METABOLISM; MENTAL DISEASE; MENTAL HEALTH; NEUROLOGIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MENTAL DISORDERS;

EID: 22444448148     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2005.8.133     Document Type: Review

References (94)

1. Shahidi F, Miraliakbari H: Omega-3 (n-3) fatty acids in health and disease: Part 1 - cardiovascular disease and cancer. J Med Food 2004;7:387-401.
2. Shoda R, Matsueda K, Yamato S, Umeda N: Therapeutic efficacy of n-3 polyunsaturated fatty acid in experimental Crohn's disease. J Gastroenterol 1995;30:98-101.
3. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy TA: Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 2003;100:1751-1756.
4. Mantzioris E, Cleland LG, Gibson RA, Neumann MA, Demasi M, James MJ: Biochemical effects of a diet containing foods enriched with n-3 fatty acids. Am J Clin Nutr 2000;72:42-48.
5. Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, Albers R, Williams CM, Calder PC: Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am J Clin Nutr 2003;77:1287-1295.
6. Tilley DG, Maurice DH: Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 2002;62:497-506.
7. Podolsky DK: Inflammatory bowel disease. N Engl J Med 1991; 325:928-934.
8. Van de Merwe JP, Schroder AM, Wensinck F, Hazenberg MP: The obligate anaerobic fecal flora of patients with Crohn's disease and their first-degree relatives. Scand J Gastroenterol 1988;23:1125-1131.
9. Shoda R, Matsueda K, Yamato S, Umeda N: Epidemiologic analysis of Crohn's disease in Japan: Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn's disease in Japan. Am J Clin Nutr 1996;63:741-745.
10. Nieto N, Torres MI, Rios A, Gil A: Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 2002;132:11-19.
11. Empey LR, Jewell LD, Garg ML, Thomson AB, Clandinin MT, Fedorac RN: Fish oil-enriched diet is mucosal protective against acetic-acid induced colitis in rats. Can J Physiol Pharmacol 1991; 69:480-487.
12. Alsan A, Triadafilopoulos G: Fish oil fatty acid supplementation in active ulcerative colitis: A double blind, placebo controlled, crossover study. Gut 1993;35:345-357.
13. Kromann N, Green A: Epidemiological studies in the Upernavik District, Greenland. Incidence of some chronic diseases 1950-1974. Scand Med J 1980;208:401-406.
14. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M: Effect of an enteric-coated fish oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334:1557-1560.
15. Lorenz-Meyer H, Bauer P, Nicolay C, Schultz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V. Carr L: Omega-3 fatty acids and low carbohydrate diet for the maintainance of remission in Crohn's disease. A randomized controlled multicenter trial (German Crohn's Disease Study Group). Scand J Gastroenterol 1996;31:778-785.
16. Middleton SJ, Naylor S, Woolner J, Hunter JO: A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 2002;16:1131-1135.
17. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, Ellis DM, Tortorella MD, Pratta MA, Hollis JM, Wynn R, Duke JL, George HJ, Hillman MC, Murphy K, Wiswall BH, Copeland RA, Decicco CP, Bruckner R, Nagase H, Itoh Y, Newton RC, Magolda RL, Trzaskos JM, Hollis GF, Arner EC, Burn TC: Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-23450.
18. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJT, Rowan AD, Shingleton WD: The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998;41:1760-1771.
19. Sandy JD, Neame PJ, Boynton RE, Flannery CR: Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266:8683-8685.
20. Cleland LG, James MJ, Proudman SM: The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003;69:845-853.
21. Kremer JM, Bigauoette J, Michalek AV, Timchalk MA, Lininger L, Rynes RI, Huyck C, Zieminski J: Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985;1:184-187.
22. Volker D, Fitzgerald P, Major G, Garg M: Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 2000;27:2305-2307.
23. Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J: Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, ontrolled study. Arthritis Rheum 1994;37:824-829.
24. Ono K, Lindsey ES: Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969;57:225-229.
25. Alexander JW, Valente JF, Greenberg NA, Custer DA, Ogle CK, Gibson SW, Babcock GF: Dietary n-3 and n-9 fatty acid uniquely enhance allograft survival in cyclosporin treated and donor specific treated rats. Transplantation 1998;65:1304-1309.
26. Homan van der Heide JJ, Bilo H, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993;329:769-773.
27. Hernández D, Guerra R, Milena A, Torres A, García G, García C, Abreu P, González A, Gómez MA, Rufino M, González-Posada J, Lorenzo V, Salido E: Dietary fish oil does not influence acute rejection rate and graft survival after renal transplantation: A randomized placebo-controlled study. Nephrol Dial Transplant 2002;17:897-904.
28. Mihrshahi S, Peat JK, Marks GB, Mellis CM, Tovey ER, Webb K, Britton WJ, Leeder SR: Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS). J Allergy Clin Immunol 2003;111:162-168.
29. Leaf A, Webber PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988;318:549-557.
30. Burney P, Chinn S, Rona RJ: Has the prevalence of asthma increased in children? Evidence from the National Study of Health and Growth 1973-86. BMJ 1990;300:1306-1310.
31. Peat JK, Salome CM, Woolcock AJ: Factors associated with bronchial hyperresponsiveness in Australian adults and children. Eur Respir J 1992;5:921-929.
32. Koch T, Duncker HP, Klein A, Schlotzer E, Peskar BM, van-Ackern K, Neuhof H: Modulation of pulmonary vascular resistance and edema formation by short-term infusion of a 10% fish oil emulsion. Infusionsther Transfusionsmed 1993;20:291-300.
33. Abeywardena MY, Jablonskis LT, Head RJ: Dietary n-3 and n-6 polyunsaturated oils and airway contractility. Prostaglandins Leukot Essent Fatty Acids 2001;64:281-287.
34. Omura M, Kobayashi S, Mizukami Y, Mogami K, Todorki-Ikeda N, Miyake T, Matsuzaki M: Eicosapentaenoic acid (EPA) induces Ca2+ independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 2001;487:361-366.
35. Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ: Consumption of oily fish and childhood asthma risk. Med J Aust 1996;164:137-140.
36. Troisi RJ, Willet WC, Weiss ST, Trichopoulos D, Rosner B, Speizer FE: A prospective study of diet and adult-onset asthma. Am J Respir Crit Care Med 1995;151:1401-1408.
37. Nagakura T, Matsuda S, Shichijo K, Sugimoto H, Hata K: Dietary supplementation with fish oil rich in n-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000;16:861-865.
38. Emelyanov A, Fedoseev G, Kranoschekova O, Abulimity A, Trendeleva T, Barnes PJ: Treatment of asthma with lipid extract of New Zealand green-lipped mussel: A randomized clinical trial. Eur Respir J 2002;20:596-600.
39. Gottlicher M, Widmark E, Li Q, Gustafsson JA: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 1992;89:4653-4657.
40. Hertz R, Magenheim J, Berman I, Bar-Tana J: Fatty acid CoA thioesters are ligands of hepatic nuclear factor-4α. Nature 1998;392:512-516.
41. de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, Perlmann T: Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000;290:2140-2144.
42. Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, Brown MS: Unsaturated fatty acids inhibit transcription of the sterol regulatory element binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 2001;98:6027-6032.
43. Pawar A, Jump DB: Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor α activity in rat primary hepatocytes. J Biol Chem 2003;278:35931-35939.
44. Desvergne B, Wahli W: Peroxisome proliferator activated receptors: Nuclear control of metabolism. Endocr Rev 2000;20:649-688.
45. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for PPARα and β. Proc Natl Acad Sci USA 1997;94:4312-4317.
46. Muerhoff AS, Griffin KJ, Johnson EF: The peroxisome proliferator activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid ω-hydroxylase, by clofibric acid. J Biol Chem 1992;267:19051-19053.
47. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM: Molecular recognition of fatty acids by peroxisome proliferator activated receptors. Mol Cell 1999;3:397-403.
48. Ren B, Thelen AP, Peters JM, Gonzales FJ, Jump DB: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor α. J Biol Chem 1997;272:26827-26832.
49. Osborne TF: Sterol regulatory element binding proteins (SREBPs): Key regulators of nutritional homeostasis and insulin action. J Biol Chem 2000;275:32379-32382.
50. Brown MS, Goldstein JL: The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane bound transcription factor. Cell 1997;89:331-340.
51. Jump DB, Thelen AP, Mater MK: Functional interaction between sterol regulatory element binding protein-1c, nuclear factor Y, and 3,5,3′-triodothyronone nuclear receptors. J Biol Chem 2001;276: 34419-34427.
52. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL: Isoform 1c of sterol regulatory element binding protein is less active than isoform la in livers of transgenic mice and in cultured cells. J Clin Invest 1997;99:846-854.
53. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H: Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998;11:2331-2339.
54. Shimano H, Yahagi N, Amemiya-Kufo M, Shimomura I: Sterol regulatory element binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 1999;274:35832-35839.
55. Pawar A, Botolin D, Mangelsdorf DJ, Jump DB: The role of liver X receptor α in the fatty acid regulation of hepatic gene expression. J Biol Chem 2003;278:40736-40743.
56. Xu MT, Nakamura MT, Cho HP, Clarke SD: Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids: A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem 1999;274:23577-23583.
57. Sessler AM, Ntambi JM: Polyunsaturated fatty acid regulation of gene expression. J Nutr 1998;128:923-926.
58. Xu J, Teran-Garcia M, Park JH: Polyunsaturated fatty acids suppress hepatic sterol regulatory element binding protein-1 expression by accelerating transcript decay. J Biol Chem 2001;276: 9800-9807.
59. Mater MK, Thelen AP, Pan DA, Jump DB: Sterol response element binding protein-1c (SREBP1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription. J Biol Chem 2001;274:32725-32744.
60. Lu TT, Repa JJ, Mangelsdorf DJ: Orphan nuclear receptors as elixirs and fixers of sterol metabolism. J Biol Chem 2001;276: 37735-37738.
61. Hertz R, Sheena V, Kalderon B: Suppression of hepatic nuclear factor-4α by acyl-CoA thioesters of hypolipidemic peroxisome proliferators. Biochem Pharmacol 2001;61:1057-1062.
62. Liimatta M, Towle HC, ClIarke SD, Jump DB: Dietary polyunsaturated fatty acids interfere with the insulin/glucose activation of L-type pyruvate kinase gene transcription. Mol Endocrinol 1994;8:1147-1153.
63. Hayhurst GP, Lee YH, Lambert G: Hepatocyte nuclear factor 4α (NR2A1) is essential for the maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 2001;21:1393-1403.
64. Mahadik SP, Evans D, Lal H: Oxidative stress and role of antioxidant and n-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25: 463-493.
65. Bourre JM, Dumont O: Essentiality of n-3 fatty acids for brain structure and function. World Rev Nutr Diet 1991;66:103-117.
66. Martin RE, Bazan NG: Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 1992;59:318-325.
67. Martinez M: Abnormal fatty acid profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992;583:171-182.
68. Chamberlain JG: Fatty acids in human brain phylogeny. Perspect Biol Med 1996;39:436-445.
69. Neuringer M: Cerebral cortex docosahexaenoic acid is lower in formula fed than in breast fed infants. Nutr Rev 1993;51:238-241.
70. Yehuda S, Carasso RL, Motofsky DI: Essential fatty acid preparation (SR-3) raises the seizure threshold in rats. Eur J Pharmacol 1994;254:193-198.
71. Sastry PS: Lipids of the nervous tissue: Composition and metabolism. Prog Lipid Res 1985;24:69-76.
72. Mitchell DC, Nui SL, Litman BJ: DHA-rich phospholoipids optimize G-protein-coupled signalling. J Pediatr 2003;143(Suppl): S80-S86.
73. Uauy R, Hoffman DR, Mena P, Llanos A, Birch EE: Term infant studies of DHA and ARA supplementation on neurodevelopment: Results of randomized controlled trials. J Pediatr 2003; 143(Suppl):S17-S25.
74. Makrides M, Neumann MA, Gibson RA: Is dietary docosahexaenoic acid essential for term infants? Lipids 1996;31:115-119.
75. Auestad N, Montalto MB, Hall RT, Fitzgerald KM, Wheeler RE, Connor WE, Neuringer M, Connor SL, Taylor JA, Hartmann EE: Visual acuity, erythrocyte fatty acid composition, and growth in term infants fed formulas with long chain polyunsaturated fatty acids for one year. Ross Pediatric Lipid Study. Pediatr Res 1997;41:1-10.
76. Auestad N, Scott DT, Janowsky JS, Jacobsen C, Carroll RE, Montalto MB, Halter R, Qiu W, Jacobs JR, Connor WE, Connor SL, Taylor JA, Neuringer M, Fitzgerald KM, Hall RT: Visual, cognitive, and language assessments at 39 months: A follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics 2003;112:e177-e183.
77. Hoffman DR, Birch EE, Castaneda YS, Fawcett SL, Wheaton DS, Birch DG, Uauy R: Visual function in breast fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: A randomized clinical trial. J Pediatr 2003;142; 669-677.
78. Bourre JM, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G, Durand G: The effects of dietary α-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological paramenters, resistance to poisons and performance of learning tasks in rats. J Nutr 1989;119:1880-1892.
79. Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G: α-Linolenic acid deficiency alters age related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996;66:1582-1591.
80. Keller JR: Omega-3 fatty acids may be effective in the treatment of depression. Top Clin Nutr 2002;17:21-27.
81. McGrath-Hanna NK, Greene DM, Tavernier RJ, Bult-Ito A: Diet and mental health in the Arctic: Is diet an important risk factor for mental health in circumpolar peoples? A review. Int J Circumpolar Health 2003;62:228-241.
82. Tanskanen A, Hibbelin JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartianen E: Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001;52:529-531.
83. Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
84. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HFS, Puryear LJ: A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003;160:996-998.
85. Su KP, Huang SY, Chiu CC, Shen WW: Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:267-271.
86. Smith RS: The macrophage theory of depression. Med Hypotheses 1991;35:298-306.
87. Maes M: Evidence for an immune response in depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
88. Xia Z, Depierre JW, Nassberger L: Tricyclic antidepressants inhibit 1L-6, IL-1 beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T-cells. Immunopharmacology 1996;34:27-37.
89. Maes M, Bosnians E, Meltzer HY: Immunoendocrine aspects of major depression. Relationships between plasma IL-6 and soluble IL-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci 1995;245:172-178.
90. Horrobin DF: The relationship between schizophrenia and essential fatty acids and eicosanoid metabolism. Prostaglandins Leukot Essent Fatty Adds 1992;46:71-77.
91. McCreadie RG, Macdonald E, Wiles D, Campell G, Patterson JR: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and normal subjects. Br J Psychiatry 1995;167:1-8.
92. Phillips M, Erickson GA, Sabas N, Smith JP, Greenberg J: Volatile organic compounds in the breath of schizophrenic patients. J Clin Pathol 1995;48:466-469.
93. Sarsilmaz M, Songur A, Ozyurt H, Kus I, Ozen OA, Ozyurt B, Sogut S, Akyol O: Potential role of dietary omega-3 fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum. Prostaglandins Leukot Essent Fatty Acids 2003;69:253-259.
94. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS: Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry 2003;53:431-441.